Page last updated: 2024-11-07

vadimezan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID123964
CHEMBL ID71263
CHEBI ID75934
SCHEMBL ID111183
MeSH IDM0544915

Synonyms (79)

Synonym
dmxaa, >=98% (hplc), solid
NCGC00165783-01
nsc 640488
as 1404
5,6-mexaa
dmxaa ,
5,6-dimethyl xanthenone acetic acid
5,6-dimethylxanthenoneacetic acid
9h-xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-
dimethyloxoxanthene acetic acid
as1404 ,
5,6-dimethylxanthenone-4-acetic acid
5,6-dimethyl-9-oxo-9h-xanthene-4-acetic acid
asa 404
asa404
(5,6-dimethyl-9-oxo-9h-xanthen-4-yl)acetic acid
117570-53-3
r-1564
nsc-640488
as-1404
asa-404
vadimezan
chebi:75934 ,
CHEMBL71263
2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid
5,6-dimethyl-9-oxo-9h-xanthene-4-aceticacid;dmxaa,asa404
5,6-dimethylxantheonone-4-acetic acid
BCP9000616
5,6-dimethylxanthenone-4-acetic acid (dmxaa)
AKOS015918030
1ye ,
6-mexaa
unii-0829j8133h
ec 700-141-4
vadimezan [inn]
0829j8133h ,
BCPP000255
FT-0630255
(5,6-dimethyl-9-oxo-xanthen)-4-acetic acid
NCGC00165783-02
2-(5,6-dimethyl-9-oxo-9h-xanthen-4-yl)acetic acid
vadimezan [who-dd]
9h-xanthene-4-aceticacid, 5,6-dimethyl-9-oxo-
vadimezanum
(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid
smr004702863
MLS006011075
SCHEMBL111183
HY-10964
CS-5277
(5,6-dimethyl-9-oxo-9h-xanthen-4-yl)-acetic acid
5,6-dimethylxanthenone-4-acetic acid; 5,6-dimethylxantheonone-4-acetic acid
AC-24559
dmxaa (vadimezan)
DTXSID2040949
mfcd00870555
4QXR
4QXO
4QXQ
J-516547
J-003637
EX-A010
HMS3654J22
XGOYIMQSIKSOBS-UHFFFAOYSA-N
SW219898-1
DB06235
vadimezan (dmxaa)
S1537
AS-16852
BCP01949
Q7908310
SB19392
CCG-267263
nsc828317
nsc-828317
NCGC00165783-04
bdbm50511078
D5235
EN300-396606

Research Excerpts

Overview

Vadimezan is a tumor vascular-disrupting agent. It acutely disrupts blood flow within tumors and induces innate tumor immunity.

ExcerptReferenceRelevance
"Vadimezan is a tumor vascular-disrupting agent that acutely disrupts blood flow within tumors and induces innate tumor immunity."( Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).
Head, M; Jameson, MB, 2011
)
1.38

Toxicity

ExcerptReferenceRelevance
" Close collaboration with cardiology colleagues for early indicators of serious cardiac adverse events will likely minimize toxicity while optimizing the therapeutic potential of VDAs and ultimately enhancing patient outcomes."( Cardiovascular toxicity profiles of vascular-disrupting agents.
Lenihan, DJ; Subbiah, IM; Tsimberidou, AM, 2011
)
0.37
" The most frequently reported adverse events were neutropenia, fatigue, alopecia, decreased appetite, constipation and injection site pain."( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
" The aim of this study was to further investigate these pharmacokinetic DMXAA-drug interactions in the rat model."( A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S, 2001
)
0.31
" The cause of the species difference in the pharmacokinetic response to thalidomide by DMXAA is unknown, and indicates difficulties in predicting the outcome of such a combination in patients."( A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S, 2001
)
0.31
"05), elimination half-life (2."( Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Kestell, P; Paxton, JW; Tingle, MD; Zhou, S, 2002
)
0.31
" Its pharmacokinetic properties have been investigated using both in vitro and in vivo models, and the resulting data extrapolated to patients."( Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Kestell, P; Paxton, JW; Zhou, S, 2002
)
0.31
"The purpose of this phase I, dose-escalation study was to determine the toxicity, maximum tolerated dose, pharmacokinetics, and pharmacodynamic end points of 5,6-dimethylxanthenone acetic acid (DMXAA)."( 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study.
Bellenger, K; Bradley, C; Folkes, L; Galbraith, S; Gumbrell, L; Halbert, G; Loadman, P; Rustin, GJ; Stratford, M; Waller, S, 2003
)
0.32
" In both of these cases, thalidomide extends the half-life (t(1/2)) of the other drug."( Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Baguley, BC; Ching, LM; Chung, F; Kestell, P; Wang, LC, 2004
)
0.32
"Both cyclophosphamide and DMXAA have a pharmacokinetic interaction with thalidomide, increasing t(1/2) and AUC."( Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Baguley, BC; Ching, LM; Chung, F; Kestell, P; Wang, LC, 2004
)
0.32

Compound-Compound Interactions

This Phase I study was carried out to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ASA404 (vadimezan) in combination with docetaxel in Japanese patients with advanced or recurrent solid tumors.

ExcerptReferenceRelevance
"1 cDNA were effective in combination with 25 mg/kg DMXAA."( Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Pandey, S, 2001
)
0.31
"5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer."( The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.
McKeage, MJ, 2008
)
0.35
" In this study, the safety and tolerability, pharmacokinetics and pharmacodynamics of ASA404 in combination with standard therapy of paclitaxel and carboplatin (P/C) were assessed."( Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N, 2011
)
0.64
" Here, we characterized the response of subcutaneous syngeneic Colon26 murine colon adenocarcinoma tumors to PDT using the locally applied photosensitizer precursor aminolevulinic acid (ALA) in combination with a topical formulation of vadimezan."( Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.
Becker, T; Bellnier, D; Marrero, A; Morgan, J; Sunar, U,
)
0.53
"This Phase I study was carried out to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the flavonoid tumor-vascular disrupting agent ASA404 (vadimezan) in combination with docetaxel in Japanese patients with advanced or recurrent solid tumors."( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011
)
0.56
" Overall, the study demonstrated that ASA404 has an acceptable tolerability profile when combined with docetaxel at doses up to 75 mg/m(2) in Japanese patients with advanced solid tumors."( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011
)
0.37
"The study supports the enrollment of Japanese patients in the Phase III study (ATTRACT-2) of ASA404 in combination with docetaxel for the second-line treatment of advanced non-small cell lung cancer."( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011
)
0.37
" In this study, we investigated the therapeutic efficacy of the tumor-VDA ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid, or vadimezan) in combination with the mTOR inhibitor everolimus (RAD001) against RCC."( Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Azabdaftari, G; Ellis, L; Hammers, H; Lehet, K; Pili, R; Seshadri, M; Shah, P; Sotomayor, P, 2012
)
0.58
"This pre-clinical study was designed to investigate the effect of various vascular disrupting agents (VDAs) that have undergone or are in clinical evaluation, had on the oxygenation status of tumours and what effects that could have on the combination with radiation."( Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
Busk, M; Horsman, MR; Iversen, AB, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" The pharmacokinetics of DMXAA in plasma, liver and tumour tissue indicated a bioavailability of 73%."( Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Baguley, BC; Ching, LM; Kestell, P; Zhao, L, 2002
)
0.31
"5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a potent cytokine inducer, with a bioavailability of >70% in the mouse."( Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
Baguley, BC; Feng, X; Kestell, P; Paxton, JW; Zhou, S, 2004
)
0.32
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"1 monotherapies are complicated by a narrow range of effective doses, combined therapy was less dosage dependent."( Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Pandey, S, 2001
)
0.31
" Efficacy of ICAM-1-mediated antitumor immunity was significantly augmented by administration of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA), which suppressed blood supply to the tumor, leading to enhanced leukocyte infiltration, and complete tumor eradication in a gene dosage and CD8(+) T cell and NK cell-dependent fashion."( Requirements for ICAM-1 immunogene therapy of lymphoma.
Berg, RW; Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Sun, X; Yang, Y, 2003
)
0.32
" We also noted differences in the dose-response relationships for NF-kappaB activation between lymphoid and endothelial lines that were species independent."( A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines.
Baguley, BC; Ching, LM; Drummond, CJ; Kieda, C; Reddy, CB; Schooltink, MA; Woon, ST, 2005
)
0.33
" BSA-guided dosing is important."( Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Baguley, BC; Baker, SD; Jameson, MB; Li, J; Pili, R, 2008
)
0.35
" Second, the question of identifying an optimal dosing strategy for treating with an AI and a cytotoxic agent is addressed."( Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Gevertz, JL, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
xanthonesAny member of the class of xanthenes based on a xanthone skeleton.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency25.22030.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
alpha-galactosidaseHomo sapiens (human)Potency50.11874.466818.391635.4813AID2107
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Stimulator of interferon genes proteinMus musculus (house mouse)IC50 (µMol)1.20001.20001.20001.2000AID1822833
Stimulator of interferon genes proteinHomo sapiens (human)IC50 (µMol)94.50000.00180.00360.0055AID1822832; AID1822834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Stimulator of interferon genes proteinMus musculus (house mouse)EC50 (µMol)49.55000.02000.02000.0200AID1714249; AID1822827; AID1822829; AID1822837
Stimulator of interferon genes proteinMus musculus (house mouse)Kd0.32330.00001.42253.5000AID1546615; AID1575510; AID1861455
Stimulator of interferon genes proteinHomo sapiens (human)EC50 (µMol)100.00000.00581.36117.2000AID1822826; AID1822828; AID1822830; AID1822831; AID1822835; AID1822836
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
protein complex oligomerizationStimulator of interferon genes proteinHomo sapiens (human)
autophagosome assemblyStimulator of interferon genes proteinHomo sapiens (human)
activation of innate immune responseStimulator of interferon genes proteinHomo sapiens (human)
pattern recognition receptor signaling pathwayStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of defense response to virus by hostStimulator of interferon genes proteinHomo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwayStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of macroautophagyStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of protein bindingStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of type I interferon productionStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of interferon-beta productionStimulator of interferon genes proteinHomo sapiens (human)
cellular response to interferon-betaStimulator of interferon genes proteinHomo sapiens (human)
innate immune responseStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIStimulator of interferon genes proteinHomo sapiens (human)
regulation of inflammatory responseStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityStimulator of interferon genes proteinHomo sapiens (human)
protein complex oligomerizationStimulator of interferon genes proteinHomo sapiens (human)
defense response to virusStimulator of interferon genes proteinHomo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwayStimulator of interferon genes proteinHomo sapiens (human)
reticulophagyStimulator of interferon genes proteinHomo sapiens (human)
protein localization to endoplasmic reticulumStimulator of interferon genes proteinHomo sapiens (human)
cellular response to exogenous dsRNAStimulator of interferon genes proteinHomo sapiens (human)
cellular response to organic cyclic compoundStimulator of interferon genes proteinHomo sapiens (human)
antiviral innate immune responseStimulator of interferon genes proteinHomo sapiens (human)
cGAS/STING signaling pathwayStimulator of interferon genes proteinHomo sapiens (human)
proton transmembrane transportStimulator of interferon genes proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein bindingStimulator of interferon genes proteinHomo sapiens (human)
proton channel activityStimulator of interferon genes proteinHomo sapiens (human)
protein kinase bindingStimulator of interferon genes proteinHomo sapiens (human)
ubiquitin protein ligase bindingStimulator of interferon genes proteinHomo sapiens (human)
cyclic-di-GMP bindingStimulator of interferon genes proteinHomo sapiens (human)
signaling adaptor activityStimulator of interferon genes proteinHomo sapiens (human)
identical protein bindingStimulator of interferon genes proteinHomo sapiens (human)
protein homodimerization activityStimulator of interferon genes proteinHomo sapiens (human)
2',3'-cyclic GMP-AMP bindingStimulator of interferon genes proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingStimulator of interferon genes proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
Golgi membraneStimulator of interferon genes proteinHomo sapiens (human)
endoplasmic reticulum membraneStimulator of interferon genes proteinHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneStimulator of interferon genes proteinHomo sapiens (human)
Golgi membraneStimulator of interferon genes proteinHomo sapiens (human)
autophagosome membraneStimulator of interferon genes proteinHomo sapiens (human)
nucleoplasmStimulator of interferon genes proteinHomo sapiens (human)
mitochondrial outer membraneStimulator of interferon genes proteinHomo sapiens (human)
endosomeStimulator of interferon genes proteinHomo sapiens (human)
autophagosomeStimulator of interferon genes proteinHomo sapiens (human)
peroxisomeStimulator of interferon genes proteinHomo sapiens (human)
endoplasmic reticulum membraneStimulator of interferon genes proteinHomo sapiens (human)
cytosolStimulator of interferon genes proteinHomo sapiens (human)
plasma membraneStimulator of interferon genes proteinHomo sapiens (human)
cytoplasmic vesicle membraneStimulator of interferon genes proteinHomo sapiens (human)
secretory granule membraneStimulator of interferon genes proteinHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneStimulator of interferon genes proteinHomo sapiens (human)
perinuclear region of cytoplasmStimulator of interferon genes proteinHomo sapiens (human)
serine/threonine protein kinase complexStimulator of interferon genes proteinHomo sapiens (human)
STING complexStimulator of interferon genes proteinHomo sapiens (human)
autophagosomeStimulator of interferon genes proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (160)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1714251Activation of STING in human THP-1-Dual cells assessed as induction of type I IFNs by measuring stimulation of IRF pathway incubated for 48 hrs by luciferase reporter gene assay
AID1493904Induction of apoptosis in human HepG2 cells assessed as increase in cleaved caspase-3 levels co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1493875Antiproliferative activity against human MDA-MB-231 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822882Antitumor activity against mouse MC38 cells implanted in C57B16 mouse assessed as increase in MIP-1beta expression in serum at 30 ug, IT administered on day 1 and day 3 and measured after 24 hrs on day 32022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1067309Selectivity ratio of CC50 for human BJ cells to IC50 for human HT-29 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1478651Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 24 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 10.01 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1822840Metabolic stability in mouse liver microsomes assessed as parent compound remaining at 0.5 uM incubated for 10 mins2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1493894Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells co-treated with DMXAA at 1:1 molar ratio after 24 hrs by annexin-V/propidium iodide staining-based flow cytometric method relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID20523Relative measure of lipophilicity was determined by using 4'-(9-acridinylamino)-methanesulfonanilide as internal standard1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
AID1493906Induction of apoptosis in human HepG2 cells assessed as increase in cleaved PARP levels co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1478652Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 48 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 88.78 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1855663Agonist activity at STING in mouse Raw-lucia-KO-STING cells assessed as activation of ISG pathway at 50 uM incubated for 24 hrs by Quanti-Luc or Quanti-blue reagent based luminescence assay2022European journal of medicinal chemistry, Nov-05, Volume: 241Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
AID292592Activation of NF-kappaB in HECPP cells at 10 ug/mL2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling.
AID1575510Competitive binding affinity to mouse C-terminal STING domain (139 to 378 residues) in presence of c-di-GMP by isothermal titration calorimetric method2019MedChemComm, Dec-01, Volume: 10, Issue:12
Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.
AID1478648Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 24 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 88.78 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1478681Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cleaved caspase-3 expression at 24 to 96 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID292597Induction of TNF secretion in mouse splenocytes at 10 ug/mL after 4 hrs2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling.
AID230777Range of dose (highest nontoxic to minimum effective) over which 50-90% necrosis was achieved in mice1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
AID142449Compound was tested for toxicity induced in murine macrophage2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
AID1478624Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID90817Compound was tested for toxicity induced in human monocyte2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
AID1822833Displacement of fluorescein-labelled probe from wild type mouse His-tagged STING cytoplasmic domain (155 to 341 residues) by time-resolved FRET-based competition binding assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1478655Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 48 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 10.01 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1822828Agonist activity at STING in human THP1 Dual KO-STING cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1478688Decrease in MDM2 level in human MDA-MB-231 cells at 24 to 96 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1478622Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID111666Ability to cause early haemorrhagic necrosis of colon 38 tumors in mice.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
AID1493880Antiproliferative activity against human K562 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822881Antitumor activity against MC38 cells xenografted in C57B16 mouse assessed as increased in serum G-CSF at 30 ug, IT measured after 24 hrs by post treatment2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1493902Induction of apoptosis in human HepG2 cells assessed as increase in cleaved caspase-9 levels at 0.2 uM after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID292591Cytotoxicity against HECPP cells assessed as reduction of cell viability at 1000 ug/mL after 24 hrs by MTT assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling.
AID1822827Agonist activity at STING in mouse RAW-Lucia ISG cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1822839Metabolic stability in rat liver microsomes assessed as parent compound remaining at 0.5 uM incubated for 10 mins2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1478650Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 24 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 1.18 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1067304Indirect cytotoxicity against human A549 cells co-cultured with human PBMC after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1822880Antitumor activity against mouse MC38 cells implanted in C57B16 mouse assessed as increase in IL-6 expression in serum at 30 ug, IT administered on day 1 and day 3 and measured after 24 hrs on day 32022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1478659Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 96 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 10.01 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1478649Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 24 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 0.03 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID226915Potency ratio was determined against macrophages; more potent2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid.
AID226899Potency ratio as the ratio of IC50 of DMXXA against human monocytes to that of the IC50 against human monocytes.2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
AID1714250Activation of STING in mouse RAW-Lucia ISG cells assessed as induction of type I IFNs stimulation by measuring induction of IRF pathway incubated for 48 hrs by luciferase reporter gene assay assay relative to 2',3'-cGAMP
AID1478680Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cleaved PARP level at 24 to 96 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1478654Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 48 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 1.18 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1493877Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822844Binding affinity to human STING G230A/R293Q double mutant assessed as change in melting temperature at 100 uM by thermal shift assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1861455Binding affinity to mouse STING assessed as dissociation constant2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
AID1478623Antiproliferative activity against human MCF7 cells after 48 hrs by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1478656Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 96 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 88.78 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1714252Activation of STING in human THP-1-Dual cells assessed as induction of type I IFNs by measuring stimulation of IRF pathway incubated for 48 hrs by luciferase reporter gene assay relative to 2',3'-cGAMP
AID226911Potency ratio was determined against human monocytes versus DMXAA (Dimethylxanthenone-4-acetic acid)2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid.
AID1493876Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID90820Indirect antitumor effect was measured as cytotoxicity with human monocytes pretreated with compounds2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid.
AID1714254Activation of STING in human THP-1-Dual cells assessed as induction of type I IFNs by measuring stimulation of NF-kappaB pathway incubated for 48 hrs by luciferase reporter gene assay relative to 2',3'-cGAMP
AID1749749Antitumor activity against mouse CT26 cells inoculated in BALB/c mouse assessed as inhibition of tumor growth at 200 ug, IT(Intratumoral) administered on day 1,4 and 7 post inoculation2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists.
AID133480Minimum dose required when administered intraperitoneally in mice as the sodium salt in water in a single dose. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
AID1478685Increase in p53 level in human MDA-MB-231 cells at 24 to 96 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1067302Induction of TNFalpha production in human PBMC at 25 to 100 uM after 24 hrs by ELISA2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1822842Permeability of the compound at pH 7.4 by PAMPA assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1714244Induction of type I IFN production in mouse RAW-Lucia ISG-KO-STING cells at 0.08 to 100 ug/ml incubated for 48 hrs by luciferase reporter gene assay
AID1478682Decrease in caspase-9 level in human MDA-MB-231 cells at 24 to 96 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID142447Indirect antitumor effect was measured as cytotoxicity with murine macrophages pretreated with compounds2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Synthesis and biological evaluation of 3-alkoxy analogues of flavone-8-acetic acid.
AID1357474Growth inhibition of human MCF7 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, May-10, Volume: 151Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
AID1478658Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 96 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 1.18 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1493916Induction of apoptosis in human HepG2 cells assessed as upregulation of Bid expression co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1067316Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1493911Inhibition of MDM2/p53 interaction in human HepG2 cells assessed as increase in p53 to MDM2 ratio co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by Western blot method (Rvb = 0.083 No_unit)2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822836Binding affinity to human STING G230A/R293Q double mutant cytoplasmic domain (155 to 341 residues) assessed as induction of protein dimerization incubated for 1 hr by time-resolved FRET-based assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1478657Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 96 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 0.03 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1714253Activation of STING in human THP-1-Dual cells assessed as induction of type I IFNs by measuring stimulation of NF-kappaB pathway incubated for 48 hrs by luciferase reporter gene assay
AID1493886Antiproliferative activity against mouse NIH/3T3 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID292588Induction of hemorrhagic necrosis in colon 38 tumor bearing C57B1/6 mouse at 25 mg/kg, ip after 24 hrs relative to control2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling.
AID1822841Permeability of the compound at pH 5.5 by PAMPA assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1493905Induction of apoptosis in human HepG2 cells assessed as increase in cleaved caspase-9 levels co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1478635Cytotoxicity against mouse NIH/3T3 cells after 48 hrs in presence of DMXAA by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1822826Agonist activity at STING in human THP1 Dual cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1822845Binding affinity to mouse His tagged STING assessed as change in melting temperature at 100 uM by thermal shift assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1822829Agonist activity at STING in mouse RAW-Lucia ISG-KO-STING cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1478653Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 48 uM after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry (Rvb = 0.03 %)2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1493874Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1855678Toxicity in Balb/c mouse implanted with mouse CT26 cells assessed as reduction in body weight at 250 ug, IT administered on day 1,4 and 7 and measured twice per week2022European journal of medicinal chemistry, Nov-05, Volume: 241Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
AID1478626Antiproliferative activity against human COLO320 cells after 48 hrs by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1861503Binding affinity to human STING S162A/Q2661 double mutant assessed as dissociation constant2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
AID119961Optimal dose to achieve the level of activity cited in colon 38 tumors after intraperitoneal administration in mice.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid.
AID1714249Activation of STING in mouse RAW-Lucia ISG cells assessed as induction of type I IFNs stimulation by measuring induction of IRF pathway incubated for 48 hrs by luciferase reporter gene assay
AID1714255Activation of STING in human blood assessed as induction of type I IFNs incubated for 18 to 20 hrs by QUANTI-Blue assay
AID1493920Induction of apoptosis in human HepG2 cells assessed as ratio of Bax/Bcl-2 co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by Western blot method (Rvb = 0.23 No_unit)2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1493885Antiproliferative activity against human HL-7702 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1493901Induction of apoptosis in human HepG2 cells assessed as increase in cleaved caspase-3 levels at 0.2 uM after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1067308Selectivity ratio of CC50 for human BJ cells to IC50 for human A549 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1822832Displacement of fluorescein-labelled probe from wild type human His-tagged STING cytoplasmic domain (155 to 341 residues) by time-resolved FRET-based competition binding assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1067313Cytotoxicity against human A549 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1493898Cell cycle arrest in human HepG2 cells assessed as accumulation at S phase at 0.2 uM after 24 hrs by propidium iodide staining-based flow cytometric method relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822834Displacement of fluorescein-labelled probe from human cytoplasmic domain of STING G230A/R293Q double mutant (155 to 341 residues) by time-resolved FRET-based competition binding assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1067310Cytotoxicity against human BJ cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID226755Potency ratio against macrophages.2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
AID1478683Decrease in caspase-3 level in human MDA-MB-231 cells at 24 to 96 uM after 48 hrs by Western blot analysis2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1478691Cell cycle arrest in human MDA-MB-231 cells assessed as increase in accumulation at G2/M phase at 48 uM after 48 hrs by propidium iodide staining based flow cytometric method relative to control2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1478633Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1493891Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 0.2 uM after 24 hrs by annexin-V/propidium iodide staining-based flow cytometric method relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1478632Cytotoxicity against human HL-7702 cells after 48 hrs by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1822835Binding affinity to wild type human His-tagged STING cytoplasmic domain (155 to 341 residues) assessed as induction of protein dimerization incubated for 1 hr by time resolved FRET-based assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1493890Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 0.2 uM after 24 hrs by annexin-V/propidium iodide staining-based flow cytometric method relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1357472Growth inhibition of human HepG2 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, May-10, Volume: 151Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
AID1357473Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, May-10, Volume: 151Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
AID1714256Activation of STING in human blood assessed as induction of type I IFNs incubated for 18 to 20 hrs by QUANTI-Blue assay relative to 2',3'-cGAMP
AID1478634Cytotoxicity against human HL-7702 cells after 48 hrs in presence of DMXAA by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1822830Agonist activity at STING in human THP1-Dual cells assessed as NF-kappaB reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1493892Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by annexin-V/propidium iodide staining-based flow cytometric method relative to control2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID44596In vitro cytotoxicity against C13 tumor cell line2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
AID226900Potency ratio as the ratio of IC50 of DMXXA against murine macrophages to that of the IC50 against murine macrophages2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid.
AID1855676Antitumor activity against mouse CT26 cells implanted in immunocompetent Balb/c mouse assessed as suppression of tumor growth at 250 ug, IT administered on day 1,4 and 7 and measured twice per week2022European journal of medicinal chemistry, Nov-05, Volume: 241Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists.
AID1067306Indirect cytotoxicity against human A549 cells co-cultured with mouse RAW264.7 cells after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1493915Induction of apoptosis in human HepG2 cells assessed as downregulation of Bcl-xL expression co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822837Binding affinity to wild type mouse His-tagged STING cytoplasmic domain (155 to 341 residues) assessed as induction of protein dimerization incubated for 1 hr by time resolved FRET-based assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1067307Cytotoxicity against human PBMC assessed as cell viability at 50 uM after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, selective cytotoxicities and probable mechanism of action of 7-methoxy-3-arylflavone-8-acetic acids.
AID1822831Agonist activity at STING in human THP1-Dual KO-STING cells assessed as NF-kappaB reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1493879Antiproliferative activity against human HepG2 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822838Metabolic stability in human liver microsomes assessed as parent compound remaining at 0.5 uM incubated for 10 mins2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID1493878Antiproliferative activity against human K562 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1822843Binding affinity to wild type human His tagged STING assessed as change in melting temperature at 100 uM by thermal shift assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Discovery of Non-Nucleotide Small-Molecule STING Agonists
AID127211Antitumor activity against the subcutaneously implanted C38 colon tumor in mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
AID1478695Induction of apoptosis in human MDA-MB-231 cells after 48 hrs by Annexin-V/FITC/PI staining based flow cytometry2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1493899Cell cycle arrest in human HepG2 cells assessed as accumulation at S phase co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by propidium iodide staining-based flow cytometric method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1493873Antiproliferative activity against human MCF7 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1546615Binding affinity to mouse STING by ITC assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Targeting Stimulator of Interferon Genes (STING): A Medicinal Chemistry Perspective.
AID1493903Induction of apoptosis in human HepG2 cells assessed as increase in cleaved PARP levels at 0.2 uM after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions.
AID1478625Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Cell reports, Sep-25, Volume: 8, Issue:6
Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (263)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's41 (15.59)18.2507
2000's110 (41.83)29.6817
2010's91 (34.60)24.3611
2020's21 (7.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.41 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (5.88%)5.53%
Reviews30 (11.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other226 (83.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-label, Multi-center Study to Evaluate the Effects of ASA404 Alone and in Combination With Taxane-based Chemotherapy on the Pharmacokinetics of Simvastatin, Caffeine, Omeprazole, and Diclofenac in Patients With Advanced Solid Tumor Malignancies [NCT01290380]Phase 154 participants (Actual)Interventional2010-02-28Terminated
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-center Study of ASA404 in Combination With Docetaxel in Second-line Treatment of Patients With Locally Advanced or Metastatic (Stage IIIb/IV) Non-small Cell Lung Cancer (NSCLC) [NCT00738387]Phase 3900 participants (Actual)Interventional2008-12-31Terminated
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With NSCLC [NCT00674102]Phase 115 participants (Actual)Interventional2008-04-30Completed
A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors [NCT01285453]Phase 19 participants (Actual)Interventional2009-03-31Completed
A Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effects of Fluvoxamine on the Pharmacokinetics of ASA404 in Adult Patients With Solid Tumor Malignancies [NCT01299415]Phase 117 participants (Actual)Interventional2009-08-31Terminated
An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Excretion (ADME) of ASA404 After a Single Intravenous Infusion of 3000 mg [14C]ASA404 in Patients With Advanced Solid Tumor Malignancies [NCT01299701]Phase 17 participants (Actual)Interventional2008-12-31Terminated
A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors [NCT01031212]Phase 10 participants (Actual)Interventional2010-01-31Withdrawn(stopped due to The investigator has left the institution (UCSF) prior to study start-up)
Carboplatin and Paclitaxel Plus ASA404 as First Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial [NCT01057342]Phase 217 participants (Actual)Interventional2010-01-31Completed
A Multi-center, Open-label, Dose-escalation Study in Patients With Advanced Cacner to Determine the Effect of the ASA404 Infusion Rate and Co-administration With the Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokinetics of Free and Tota [NCT01240642]Phase 127 participants (Actual)Interventional2010-01-31Terminated
Phase I Trial of 5,6 Dimethylxanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors [NCT00863733]Phase 163 participants (Actual)Interventional1996-05-31Completed
An Open Label, Randomized, Phase I/II Study of DMXAA in Combination With Carboplatin and Paclitaxel in Patients With Locally Advanced and Metastatic Non-Small Cell Lung Cancer [NCT00832494]Phase 1/Phase 2105 participants (Actual)Interventional2004-09-30Completed
A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144 [NCT01071928]Phase 20 participants (Actual)Interventional2010-06-30Withdrawn(stopped due to Lack of efficacy of experimental treatment)
An Open Label, Randomized, Phase II Study of AS1404 in Combination With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer [NCT00111618]Phase 270 participants (Anticipated)Interventional2005-05-31Completed
A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of ASA404 in Adult Cancer Patients With Impaired Hepatic Function and With Normal Hepatic Function [NCT01278849]Phase 15 participants (Actual)Interventional2010-01-31Terminated
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC) [NCT00662597]Phase 31,285 participants (Actual)Interventional2008-04-30Terminated
A Phase I Trial of 5, 6 Dimethyl Xanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors [NCT00003697]Phase 13 participants (Anticipated)Interventional1995-10-31Completed
A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function [NCT01278758]Phase 17 participants (Actual)Interventional2010-03-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]